Aggressive cutaneous follicular lymphoma in a 18F-FDG PET/CT study.

Aggressive cutaneous follicular lymphoma in a 18F-FDG PET/CT study. Med Clin (Barc). 2019 Oct 14;: Authors: Martínez-Esteve A, Moreno-Caballero M, Jiménez-Granero P, Cobo-Rodríguez A, Infante-de-la-Torre JR, Serrano-Vicente J, Rayo-Madrid JI, Martín-Marcuartu JJ PMID: 31623822 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Related Links:

PMID: 31742489 [PubMed - in process]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Publication date: Available online 20 November 2019Source: Biosensors and BioelectronicsAuthor(s): Adele De Ninno, Riccardo Reale, Alessandro Giovinazzo, Francesca R. Bertani, Luca Businaro, Paolo Bisegna, Claudia Matteucci, Federica CaselliAbstractThe study and the characterization of cell death mechanisms are fundamental in cell biology research. Traditional death/viability assays usually involve laborious sample preparation and expensive equipment or reagents. In this work, we use electrical impedance spectroscopy as a label-free methodology to characterize viable, necrotic and apoptotic human lymphoma U937 cells. A s...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Abstract Radiation therapy plays a critical role in the management of a wide range of hematologic malignancies. The optimal radiation dose and target volume, and safe and effective ways of integrating radiation with systemic agents, vary depending on the histologic subtypes, stage at presentation, patient performance status, response to systemic therapy if given, treatment intent, and patient preferences. Limiting doses to surrounding organs without sacrificing disease control is of paramount importance. Reducing radiation doses and treatment volume in selected cases, and the use of advanced radiotherapy technolog...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Hematol Oncol Clin North Am Source Type: research
Sarcoidosis is a systemic disease of unknown origin, characterised by the presence of noncaseating granulomas at disease sites [1]. A relevant clinical problem in the management of this disease is the coexistence of other clinical conditions, such as solid tumours or lymphomas, that may occur before or following the diagnosis of sarcoidosis, as well as simultaneously [2]. Particularly, the association of sarcoidosis and lymphoma is well established and was named the "sarcoidosis–lymphoma syndrome" by Brincker [3] and colleagues in 1986. In this syndrome, lymphoma occurs mainly in patients with a chronic act...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
Conclusion: The overall characteristics of SAP deficiency in mainland China were consistent with those in previous reports, whereas manifestations of XIAP deficiency varied significantly. None of inflammatory bowel disease (IBD) has been reported among XIAP-deficient patients in our center; however, whether Chinese XIAP-deficient patients will develop colitis in the future warrants further investigation. HSCT is the only curative therapy for XLP and this therapy should be urgently considered.What is Known:•SAP and XIAP deficiencies share common clinical feature,HLH,whereas they also have their own specific manifestati...
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion83.3% of the non-conjunctival origin OAML were FDG-avid tumors, with FDG PET/CT showing comparable sensitivity to that of MRI. FDG PET/CT detected unsuspected extraocular lymphoma involvement in 14% of the patients. FDG PET/CT performed for staging of non-conjunctival origin OAML may thus guide therapeutic management.
Source: EJNMMI Research - Category: Radiology Source Type: research
As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
ConclusionInguinal lymphocele that is not reabsorbed or does not resolve with conservative treatment should be surgically treated. Lymphocele excision with ligation of lymphatic vessels, followed by negative pressure wound therapy appears to be a safe and effective approach.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
No abstract available
Source: Journal of Clinical Neuromuscular Disease - Category: Neurology Tags: Letters to the Editor Source Type: research
More News: General Medicine | Lymphoma | Study